Pulmatrix, Inc. (PULM) Form 424B3 — Sep 25, 2026
Pulmatrix filed a proxy statement/prospectus for its reverse merger with Eos SENOLYTIX, under which it will issue 75,245,366 total shares (54.4M to Eos holders/financing investors, plus 20.9M for new warrants, options and RSUs). Existing Pulmatrix holders will retain only ~6% of the combined company, valued at approximately $7.85 million under a $100 million Eos pre-money valuation. The special meeting on October 16, 2026 will vote on the Nasdaq stock issuance, a reverse stock split of 1-for-2 to 1-for-10, an increase in authorized shares to 250 million, and related proposals — approvals of Proposals 1, 2 and 3 are conditions to closing.
Key figures
- Shares Offered
- 75245366
- Ceo rsu shares
- 13000000
- Shares to eos holders
- 54359630
- Eos pre money valuation
- $100.0 million
- Estimated exchange ratio
- 8.55 Pulmatrix shares per Eos share
- Authorized share increase
- 200,000,000 to 250,000,000
- Reverse split ratio range
- 1:2 to 1:10
- Closing price sept 24 2026
- $1.67
- Anticipated capital raising
- $18.0 million
- Shares outstanding record date
- 3652285
- Implied value of pulmatrix 6pct
- $7.85 million
- Shares for warrants options rsus
- 20885736
- Eos holders ownership post merger
- ~94%
- Min eos financing proceeds condition
- $13,000,000
- Pulmatrix holders ownership post merger
- ~6% fully diluted (excl. CEO RSUs)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.